- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02610543
UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome
A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy of UCB5857 Over 12 Weeks in Subjects With Primary Sjögren's Syndrome
This is a Phase 2, multicenter, double-blind, placebo-controlled, 12-week proof-of-concept study to assess the efficacy, safety, and tolerability of UCB5857 in subjects with primary Sjögren's Syndrome (pSS).
The primary objective of this study is to evaluate the efficacy on overall disease activity and safety of UCB5857 added to current treatment relative to placebo in subjects with pSS.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Brest, France
- Ss0004 34
-
Le Kremlin-Bicêtre, France
- Ss0004 30
-
Strasbourg, France
- Ss0004 35
-
-
-
-
-
L'Aquila, Italy
- Ss0004 20
-
Palermo, Italy
- Ss0004 21
-
Udine, Italy
- Ss0004 22
-
-
-
-
-
Cordoba, Spain
- Ss0004 42
-
Villajoyosa, Spain
- Ss0004 40
-
-
-
-
-
Stockholm, Sweden
- Ss0004 50
-
-
-
-
-
Birmingham, United Kingdom
- Ss0004 01
-
Essex, United Kingdom
- Ss0004 05
-
Leeds, United Kingdom
- Ss0004 04
-
Newcastle upon Tyne, United Kingdom
- Ss0004 03
-
Swindon, United Kingdom
- Ss0004 02
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject must be between 18 years and 75 years of age
- Women of childbearing potential must agree to use a highly effective method of birth control during the study and for a period of 3 months after their final dose of study drug. Women not agreeing to use birth control must be of non-childbearing potential defined as; permanently sterile, congenitally sterile or postmenopausal for at least 2 years prior to Screening (Visit 1). Women of childbearing potential are required to have a serum pregnancy test taken at Screening (Visit 1), which is confirmed to be negative by urine testing prior to the first dose of study drug at Week 1 (Visit 2) Male subjects with a partner of childbearing potential must be willing to use a condom when sexually active during the study and for 3 months after the last dose of study drug In addition female partner of childbearing potential of male subject must be willing to use a highly effective method of contraception for duration of study and for 3 months after last dose of study drug
- Subject must meet the 2002 AECG (American-European Consensus Group) criteria for Primary Sjӧgren's Syndrome
- Subject must have a serum test positive for anti-SSA/Ro (Ro-52 or Ro-60) and/or anti SSB/La autoantibodies
Exclusion Criteria:
- Subject has a diagnosis of any other autoimmune disease, ie, secondary Sjögren's syndrome (eg, rheumatoid arthritis, systemic lupus erythematosus
- Subject has a diagnosis of any other sicca syndrome (eg, history of head and neck radiation treatment, sarcoidosis chronic graft-versus-host disease)
- Subject has significant fibromyalgia syndrome as defined by the American College of Rheumatology 2010 classification criteria
- Subject has significant depression as defined by the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders
- Subject has oral candidiasis
- Subject is female and is breast-feeding, pregnant, or plans to become pregnant or to start breastfeeding during the study or within 3 months after the final dose of the investigational medicinal product (IMP)
Subject has evidence of an immunosuppressive state, including human immunodeficiency virus (HIV) infection, hypogammaglobulinemias, T-cell deficiencies, or human T-cell leukemia virus type 1 (HTLV-1)
o Positive testing for HIV-1/2 at Screening (Visit 1)
Subject has a history of chronic infections, including but not limited to concurrent acute or chronic viral hepatitis B (HBV) or hepatitis C (HCV)
- Positive testing for HBV at Screening (Visit 1)
- Positive testing for HCV at Screening (Visit 1)
- A subject with a history of a recent serious or life-threatening infection or any current signs or symptoms that may indicate a significant infection at Screening (Visit 1) to randomization, as per the Investigator's clinical judgment is also excluded Subject must have completed any prior anti-infective therapy prior to the first dose of study drug with the exception of anti-infectives taken specifically for the treatment of acne, rosacea, onychomycosis, or vaginal yeast infections; for the prophylaxis of urinary tract infections; or prophylaxis for pre-surgical or pre-procedural reasons (including dental procedures). Note: minocycline may not be used for these purposes
- Subject is at a particularly high risk of significant infection due to their lifestyle and/or occupation
- Subject has received intranasal influenza vaccine within the 8 weeks prior to Screening (Visit 1)
- Subject has significant hematologic abnormalities of hemoglobin <10.0 g/dL, or white blood cell (WBC) <2000 /mm^3, or absolute neutrophil count <1000 /mm^3, or platelets <100,000 /mm^3 at Screening (Visit 1)
- Subject has a history of cancer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: UCB5857
UCB5857 once daily for 12 weeks
|
Active Substance: UCB5857 Pharmaceutical form: Capsule Concentration: 5 mg, 10 mg, 30 mg Route of administration: oral
|
Placebo Comparator: Placebo
Placebo once daily for 12 weeks
|
Active substance: Placebo Pharmaceutical Form: Capsule Route of administration: oral
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline to Week 12 in the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI)
Time Frame: Week 12
|
The ESSDAI is a physician administered questionnaire containing 12 organ-specific domains designed to measure disease activity
|
Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline to Week 4 in the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI)
Time Frame: Week 4
|
The ESSDAI is a physician administered questionnaire containing 12 organ-specific domains designed to measure disease activity
|
Week 4
|
Change from Baseline to Week 8 in the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI)
Time Frame: Week 8
|
The ESSDAI is a physician administered questionnaire containing 12 organ-specific domains designed to measure disease activity
|
Week 8
|
Change from Baseline to Week 4 in the EULAR Sjögren's Syndrome Patient Response Index (ESSPRI)
Time Frame: Week 4
|
The ESSPRI is a patient completed questionnaire to assess subjective patient symptoms, which includes 3 domains (dryness, limb pain and fatigue)
|
Week 4
|
Change from Baseline to Week 8 in the EULAR Sjögren's Syndrome Patient Response Index (ESSPRI)
Time Frame: Week 8
|
The ESSPRI is a patient completed questionnaire to assess subjective patient symptoms, which includes 3 domains (dryness, limb pain and fatigue)
|
Week 8
|
Change from Baseline to Week 12 in the EULAR Sjögren's Syndrome Patient Response Index (ESSPRI)
Time Frame: Week 12
|
The ESSPRI is a patient completed questionnaire to assess subjective patient symptoms, which includes 3 domains (dryness, limb pain and fatigue)
|
Week 12
|
Change from Baseline to Week 4 in the stimulated salivary flow
Time Frame: Week 4
|
The stimulated salivary flow test evaluates the status of salivary glands and the production of saliva.
Saliva is collected into a graduated container after gustatory provocation with a stimulant
|
Week 4
|
Change from Baseline to Week 8 in the stimulated salivary flow
Time Frame: Week 8
|
The stimulated salivary flow test evaluates the status of salivary glands and the production of saliva.
Saliva is collected into a graduated container after gustatory provocation with a stimulant
|
Week 8
|
Change from Baseline to Week 12 in the stimulated salivary flow
Time Frame: Week 12
|
The stimulated salivary flow test evaluates the status of salivary glands and the production of saliva.
Saliva is collected into a graduated container after gustatory provocation with a stimulant
|
Week 12
|
Change from Baseline to Week 4 in the unstimulated salivary flow
Time Frame: Week 4
|
The unstimulated salivary flow test evaluates the status of salivary glands and the production of saliva.
Saliva is collected into a graduated container without gustatory provocation
|
Week 4
|
Change from Baseline to Week 8 in the unstimulated salivary flow
Time Frame: Week 8
|
The unstimulated salivary flow test evaluates the status of salivary glands and the production of saliva.
Saliva is collected into a graduated container without gustatory provocation.
|
Week 8
|
Change from Baseline to Week 12 in the unstimulated salivary flow
Time Frame: Week 12
|
The unstimulated salivary flow test evaluates the status of salivary glands and the production of saliva.
Saliva is collected into a graduated container without gustatory provocation
|
Week 12
|
Change in sum total tear secretion from Baseline to Week 12 measured by Schirmer´s I test(without anesthesia)
Time Frame: Week 12
|
The Schirmer's test measures basic tear function.
A 35 mm x 5mm size paper strip is inserted into each eye for a period of 5 minutes to measure the production of tears.
|
Week 12
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: UCB Cares, +18445992273 (UCB)
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Autoimmune Diseases
- Eye Diseases
- Disease
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Stomatognathic Diseases
- Mouth Diseases
- Lacrimal Apparatus Diseases
- Arthritis, Rheumatoid
- Xerostomia
- Salivary Gland Diseases
- Dry Eye Syndromes
- Syndrome
- Sjogren's Syndrome
Other Study ID Numbers
- SS0004
- 2014-004523-51 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Sjögren's Syndrome
-
argenxIqvia Pty LtdRecruitingPrimary Sjögren's SyndromeBelgium, Hungary, Poland
-
Assistance Publique - Hôpitaux de ParisRecruitingPrimary Sjögren's Syndrome (pSS)France
-
Peking University People's HospitalRecruitingPrimary Sjögren's SyndromeChina
-
Second Affiliated Hospital, School of Medicine,...RecruitingPrimary Sjögren's SyndromeChina
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
RemeGen Co., Ltd.CompletedA Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's SyndromePrimary Sjögren's SyndromeChina
-
University Hospital, Strasbourg, FranceCompletedPrimary Sjögren's Syndrome (pSS)France
-
National Institute of Allergy and Infectious Diseases...Biogen; Autoimmunity Centers of ExcellenceTerminatedPrimary Sjögren's SyndromeUnited States
-
Novartis PharmaceuticalsWithdrawnPrimary Sjögren's Syndrome
-
argenxIqvia Pty LtdActive, not recruitingPrimary Sjögren's SyndromeBelgium, Poland, Hungary, Netherlands
Clinical Trials on UCB5857
-
UCB PharmaParexelCompleted
-
UCB CelltechParexelCompletedHealthy VolunteersUnited Kingdom